Biohaven Pharmaceutical Holding Company
Biohaven Pharmaceutical Holding Company is a Clinical Stage Biopharmaceutical company. It portfolio is comprised of innovative, late stage product candidates targeting neurological and neuropsychiatric diseases including rare disorders. The company is rapidly progressing multiple compounds in clinical trials across three platforms they are calcitonin gene related peptide receptor antagonism, glutamate modulation and myeloperoxidase inhibition. The headquarters is in USA.